Inhibitec
Anticuerpos S.L.

BAMBI (BMP and Activin Membrane-Bound Inhibitor) blockade as a new therapeutic option for patients with Psoriatic Arthritis

Ramón Merino
October, 18 2019

Nearly 40% of Psoriatic Arthritis patients do not demonstrate a satisfactory response to existing therapies

- Psoriasis is a chronic inflammatory disorder affecting the skin and joints that has a major impact on socioeconomic aspects of a patient's life.





- More than 125 million individuals (2–3% of global population) are affected by psoriasis and 30% of them also develop Psoriatic Arthritis (PsA).

- **With the existing therapies 35-40% of patients with PsA do not reach a minimum level of efficacy (ACR 20% joint response level) and the appearance of drug resistances is frequent.**

- **There is a need to identify new molecular targets and treatments in PsA that improve existing therapies.**

Existing therapies target the IL-23/IL-17A T_{H17} axis



Inhibitec
Anticuerpos S.L.

Inhibitec's novel compound simultaneously targets Treg and TH17 cells

- ***Our Target: BAMBI (BMP and Activin Membrane-Bound Inhibitor) is an inhibitor of TGFβ signalling.***
- ***Our Product: B101.37, an inhibitory IgG1 anti-mouse and human BAMBI mAb.***



B101.37 demonstrates in vivo preclinical efficacy equivalent to existing standard of care



Macroscopic skin psoriasis

Histopatological skin psoriasis

Macroscopic PsA

Normal Mice | ***Untreated Diseased Mice*** | ***B101.37-Treated Diseased Mice***

In this preclinical model the efficacy of B101.37 therapy is similar to anti-IL-17A therapy.

Inhibitec Anticuerpos S.L.

Future development will position B101.37 as a new gold standard in the management of PsA

Our Goal	●To find a cost-effective, timely approach to provide PsA patients with a new standard of care that more effectively treats their condition. ●To introduce B101.37 into clinical phases
Our Strategy	●To initiate trials in PsA patients with poor responses to existing therapies.
Our Sequenced Growth Opportunity	●To expand clinical testing to treatment-naive patients with the goal of demonstrating superior response to existing therapies, including biosimilars that will be available as treatment options in the future.

Inhibitec
Anticuerpos S.L.

Inhibitec will require 3M € and 3 years to humanize the antibody and complete preclinical development

Milestone	Time	Steps/output/results	Cost Estimate
B101.37 Humanization	End 2019 (10 months)	Externalized	0.4 M €
Preclinical Assays	September 2020 (14 months)	Assessment of hu-B101.37 efficacy in our preclinical models of PsA	0.8 M €
Toxicity under regulatory conditions	December 2020 (18 months)	Externalized	1 M €
Pharmacology	December 2020 (18 months)	Externalized	0.8 M €

Inhibitec Anticuerpos S.L.

Business and Scientific multi-skilled team: Pharma and Biotech industries, M&A and Funding, Research Scientists

Gabriel Mesquida: Agronomic Engineer, MBA, Partner Eurohold, CFO in Telecom Equipment Company, Sole administrator Inhibitec-Anticuerpos S.L.

Eduardo Quemada: Civil Engineer, MBA IESE Business School, General Manager, PlantResponse Biotech.

Josep Mª Piqueras: Pharmacist, MBA, Senior Advisor in Eurohold, large experience in Pharma Industry: Kern Pharma (former General Manager), Roche, Boehringer Mannheim.

Joaquín Alberto Palma: Biologist, General Manager of STIG Group (Financial Services Company).

Pascal Albert Vieilledent: D.E.S.C.A.F., General Manager of Eurohold (M&A Company).

Ramón Merino: MD., PhD, Staff Scientist at the Spanish National Research Council, Associate Professor, University of Cantabria.

Jesús Merino: MD., PhD, Professor of Immunology, University of Cantabria.

Inhibitec
Anticuerpos S.L.

Inhibitec-Anticuerpos S.L. identifies a new molecular target in PsA, BAMBI, and develop an inhibitory mAbs, B101.37.

Inhibitec-Anticuerpos plans to position B101.37 as a new gold standard in the management of PsA.

Inhibitec
Anticuerpos S.L.

Instituto de Biomedicina y Biotecnología de Cantabria
C/ Albert Einstein 22, 39011 Santander, Spain.